Letrozole vs observation for HR positive breast cancer

Bookmark and Share
Published: 31 May 2015
Views: 2179
Rating:
Save
Dr Nicholas Zdenkowski - University of Newcastle, Newcastle, Australia

Dr Zdenkowski talks to ecancertv at ASCO 2015 about the final analysis of a randomised comparison of letrozole versus observation as late reintroduction of adjuvant endocrine therapy (AET) for postmenopausal women with hormone receptor positive breast cancer after completion of prior AET.

The results show that in postmenopausal women who had completed four or more years of AET for hormone receptor positive breast cancer showed significantly reduced the incidence of late invasive breast cancer events.